

Media backgrounder: Brunswick site expansion

Overview

Mölnlycke Health Care is investing \$135 million to expand its Wound Care manufacturing facility in Brunswick, Maine, USA. The project will add 78,000 square feet to Mölnlycke's existing 64,000 square feet site at Brunswick Landing.

Construction will officially commence with a groundbreaking ceremony on September 23, 2025. The expanded facility is expected to be completed by late 2026 or early 2027.

Strategic purpose of the expansion

- **Localisation**: Part of Mölnlycke's global strategy to manufacture products closer to where they are sold.
- **Customer demand**: Responds to growing demand from U.S. healthcare providers for advanced wound care solutions.
- **Supply chain resilience**: Reduces exposure to risks and uncertainties such as pandemics, geopolitical issues, natural disasters, and tariffs.
- Sustainability: Supports Mölnlycke's commitment to sustainable, efficient and reliable healthcare delivery.

Why Brunswick?

- Mölnlycke has operated in Brunswick since 2013, with a proven track record of high-quality manufacturing and a skilled, dedicated workforce.
- The location offers strong infrastructure and access to a local talent pool, making it ideal for continued investment and growth.
- The location is appealing to employees who live locally or within a reasonable commute.

Products manufactured in Maine

Currently, the Brunswick facility produces a range of advanced wound care dressings, including:

- Mepilex®
- Mepilex® Border Flex
- Mepilex® Border Sacrum
- Mepilex® Border Heel

The expansion will enable Mölnlycke to manufacture more product lines at the Brunswick site in the future.



Job creation

- The expansion is expected to create approximately 30 new jobs in Maine.
- Current Mölnlycke employee numbers:
 - o Brunswick: 130
 - o Maine (total): 270
 - o U.S.: 734
 - o Global: 8.617

Mölnlycke's legacy in Maine

- Mölnlycke's journey in Maine began in 1998 through a partnership with a local foam technology company that was founded in East Boothbay in 1973.
- In 2005, a new facility was built in Wiscasset to meet growing global demand.
- Mölnlycke acquired the company in **2010**, establishing its first North American manufacturing site.
- In 2011, Mölnlycke broke ground on the Brunswick facility—the first "green field" development at the former Brunswick Naval Air Station.
- Today, both Wiscasset and Brunswick are thriving production sites.

Mölnlycke in the U.S.

- Manufacturing sites: Brunswick (ME), Wiscasset (ME), Indianapolis (IN)
- U.S. headquarters: Atlanta, Georgia
- U.S. sales: Over \$600 million (2024)
- Employees: 734

About Mölnlycke

Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB with global headquarters in Gothenburg, Sweden. More details: www.molnlycke.com

Additional information and media assets

Media room: Mölnlycke Brunswick, Maine site expansion